Study on the Performance and Safety of Sentinox in COVID-19 Patients

NACompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

November 30, 2021

Study Completion Date

November 30, 2021

Conditions
COVID-19 (SARS-CoV-2 Infection)
Interventions
DEVICE

Sentinox--Group A

"GROUP A: Sentinox treatment performed 3 times/day for 5 days (as addon to the standard therapy) at 8am, 2pm and 8pm;~The application of IP on should be performed in accordance to the following indication:~The treatment is administered in a dose of 0.5 ml into each nostril (5 sprays) per the number of times per day according the trial group assigned according the randomization procedure (i.e., GROUP A: 3 times/day; GROUP B: 5 times/day; GROUP C: no IP treatment)."

DEVICE

Sentinox--Group B

"GROUP B: Sentinox treatment performed 5 times/day for 5 days (as addon to the standard therapy) at 8am, 11am, 2pm, 5pm and 8pm;~The application of IP on should be performed in accordance to the following indication:~The treatment is administered in a dose of 0.5 ml into each nostril (5 sprays) per the number of times per day according the trial group assigned according the randomization procedure (i.e., GROUP A: 3 times/day; GROUP B: 5 times/day; GROUP C: no IP treatment)."

Trial Locations (1)

16132

Ospedale Policlinico San Martino IRCCS, Genova

All Listed Sponsors
lead

APR Applied Pharma Research s.a.

OTHER